Related coverage linked through entity extraction aliases.
Apr 27, 2026
TNF-α and MMP-7 levels were higher at diagnosis in adult pulmonary Langerhans cell histiocytosis patients with declining FEV1 than in those with stable FEV1. MMP-7 levels showed a negative correlation with FEV1 values.
Apr 23, 2026
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
Apr 04, 2026
Experimental topical therapies for diabetic foot ulcers are showing early promise. Studies described probiotic-based treatments, a medieval antimicrobial mixture and a quercetin-loaded hyaluosome gel with anti-inflammatory and wound-healing effects.
Mar 23, 2026
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
Mar 19, 2026
Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.
Mar 02, 2026
Recent studies examine biological factors affecting sleep in older adults, finding connections between inflammatory markers, antioxidant capacity, and sleep quality in aging populations.
Mar 02, 2026
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
Feb 15, 2026
Researchers at Texas A&M University have developed a tissue-adhesive biosensor that detects inflammation biomarkers in the mouth with molecular precision, potentially shifting oral healthcare from reactive to proactive.
Feb 13, 2026
The European Commission has granted marketing authorization for Gotenfia, a golimumab biosimilar to Simponi, developed by Bio-Thera and to be commercialized by STADA across the EU, EEA, UK, Switzerland and selected other countries.
Feb 13, 2026
The European Commission has approved Gotenfia (golimumab), a biosimilar to Simponi developed by Bio-Thera and marketed by STADA, for chronic inflammatory autoimmune diseases across the EU and EEA.
